<DOC>
	<DOCNO>NCT00116168</DOCNO>
	<brief_summary>A Phase I studyto evaluate safety tolerability escalate subcutaneous ( SC ) dose MEDI-528 healthy adult volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics , Immunogenicity Single-Dose Subcutaneous Administration MEDI-528</brief_title>
	<detailed_description>The primary objective Phase I study evaluate safety tolerability escalate single SC dose MEDI-528 administer healthy adult volunteer four dose group .</detailed_description>
	<criteria>Males female age 19 , include , 49 year age time first dose study drug Weight le 89 kg Written inform consent obtain volunteer Healthy medical history physical examination Sexually active female , unless surgically sterile least two year postmenopausal FSH≥40 mIu/mL , must use effective method avoid pregnancy ( include oral , injectable , transdermal , abstinence , use condom sexual partner sterile sexual partner ) 3 month first dose study drug , must agree continue use precaution study period 84 day . Cessation birth control point discuss responsible physician . Sexually active male , unless surgically sterile , must likewise use effective method birth control ( condom abstinence ) must agree continue use precaution Study Day 84 dose study drug . Use common overthecounter medication topical corticosteroid , decongestant , antihistamine , analgesic , antacid permit unless , opinion investigator , would interfere either volunteer 's ability complete study interpretation study result . Ability complete followup period 84 day Willing forego form experimental treatment study period 84 day Willing forego vigorous activity 1 2 day dose , study visit . Acute illnesses evidence significant active infection , fever great equal 38.0 C ( 100.5°F ) start study Use prescription medication , oral contraceptive , 28day period Study Day 0 Any blood donation significant loss blood within 6 month time entry study History immunodeficiency receipt immunosuppressive drug History allergy reaction component MEDI528 formulation History substance abuse , opinion investigator , may compromise ability study subject complete study followup period Evidence systemic disease , neurologic abnormality , lymphadenopathy , splenomegaly upon physical examination Evidence infection hepatitis A , B , C virus HIV1 Receipt immunoglobulins blood product within 60 day enter study Receipt investigational drug therapy standard vaccine therapy , vaccination influenza , within 60 day first dose study drug Study Day 84 ( use license agent indication list package insert permit ) Receipt MEDI528 previous clinical study At Screening ( must within 21 day study dose administration ) follow : Hgb , total WBC , platelet count , Na , K , C1 , CO2 , AST , ALT , BUN , glucose , amylase , lipase , creatinine , troponin normal range ; abnormal laboratory value screen panel , opinion principal investigator , judge clinically significant Clinically significant abnormality , determine investigator , 12lead electrocardiogram time initial screen Clinically significant abnormality note baseline brain MRI Elective surgery plan study period Study Day 84 Pregnancy ( sexually active female must negative serum pregnancy test day first dose study drug , dose ) Nursing mother The presence condition concern , opinion investigator , may interfere conduct interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>